{
  "nctrialId": "HC-1623",
  "title": "A Randomized Open-Label, Active-Controlled  Study of HIV-335 (integrase inhibitor) in Patients With Osteoporosis",
  "officialTitle": "A Randomized Open-Label, Active-Controlled  Study of HIV-335 (integrase inhibitor) in Patients With Osteoporosis",
  "sponsor": "Canadian Blood Services",
  "indication": "Osteoporosis",
  "phase": "Phase 1",
  "fileName": "HC-1623.json",
  "fileSize": 116263,
  "date": "2024-03-29",
  "completionDate": "2028-04-22",
  "drugName": "HIV-335 (integrase inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Withdrawn",
  "description": "This is a randomized open-label, active-controlled  study designed to evaluate the efficacy and safety of HIV-335 (integrase inhibitor) in patients with Osteoporosis. The study will enroll approximately 77 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 25-74 years\n- Confirmed diagnosis of Osteoporosis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment",
  "csr_id": "HC-1623"
}